Sekretessinställningar
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • FemmeBryter barriärer och bygger självförtroende inom investeringar
  • Lär dig om investeringar
    • AnalysskolaLär dig läsa och förstå aktieanalys
    • InvesteringsskolaGuider och lektioner för att öka din investeringskunskap
    • PortföljinnehavareInvesteringskunskap för alla nivåer, från första stegen till avancerade portföljstrategier.
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • InsideraffärerFölj köp- och säljaktivitet hos företagsinsiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtuell analytikerchattStäll frågor och få AI-drivna investeringsinsikter direkt
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

UK digital pathology provider Source BioScience chooses Sectra to enable seamless pathology collaboration across the NHS

SECT BPressmeddelande21.09.2026 klo 10.05
Discuss

Linköping, Sweden - September 21, 2026 - International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed an agreement with Source BioScience UK Ltd (Source BioScience) in the UK to deliver its service for advanced share and collaborate workflows. As the first Sectra customer in this domain, Source BioScience will now be able to support NHS organisations that need to send pathology cases to external specialists. This lays the foundation for national telepathology networks in the UK, and for improved access to specialist pathologists.

The service, Sectra Image Exchange Portal (Sectra IEP), is a cloud-based, vendor-neutral platform for exchanging and collaborating around medical images. It is already used by more than 500 institutions, mainly within radiology. Recently, the service has undergone substantial modernisation which now makes it possible for healthcare providers to benefit from new advanced workflow functionality, for the service to be used by specialties other than radiology and for customers to move beyond image sharing to managing workflows between organisations.

 

"This milestone integration will give the NHS a seamless digital pathway to external specialists, with diagnoses delivered straight back into its own records - reducing turnaround times, easing consultant shortages and tackling reporting backlogs," says Nick Bills, Healthcare Director at Source BioScience.

 

Source BioScience is a UK laboratory services provider specialising in histopathology and genomics. Its pathology business supports more than 85 NHS trusts alongside a network of private healthcare clinics, with histopathology delivered from laboratories in Nottingham, Chichester and Cambridge.

 

NHS pathology services are handling growing case volumes with a limited number of reporting consultants, and increasing subspecialisation means the pathologist best suited to a case is often at another organisation. Sending work to external capacity providers today typically relies on bespoke arrangements between individual laboratories, including the transportation of physical glass slides. This slows reporting times and creates administrative overhead for both the sending and receiving laboratories. With Sectra's service, a case can be created as a job directly from a laboratory's worklist, delegated to a receiving organisation, and the completed report returned to the referring organisation's own records.

 

"IEP is the backbone of image sharing across the NHS. With our modernised platform, we are introducing advanced workflows between healthcare organisations, and extending that trusted national network into pathology. Connecting trusts directly with external specialists like Source BioScience means cases and completed reports move seamlessly across organisational boundaries. It is a step towards an NHS where expertise is always within reach, and where work moves between organisations as easily as it moves within them," says Jane Rendall, Managing Director for Sectra UK and Ireland.

 

The three-year contract was signed in the second quarter of Sectra's 2026/2027 fiscal year. Up to 60,000 cases are expected during the first year, scaling up in subsequent years.

 

Source BioScience Media Contact:
Klaudyna Johnstone, Commercial Director, klaudyna.johnstone@sourcebioscience.com